SEC Form 4 · accession 0001104659-17-007831
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary Sender
Officer — Chief Financial Officer
Period of report
Feb 7, 2017
Accepted (ET)
Feb 9, 2017 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Feb 7, 2017 | A | 11,300 | A | — | Feb 6, 2027 | Common Shares | 11,300 | 11,300 | D |
Explanation of responses
- F1The exercise price is 79.63 Euro.
- F2This option was granted on February 7, 2017. Vesting will begin on February 28, 2017 and end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.